The prognostic utility of NT-proBNP among people with type 2 diabetes has also been investigated in the Dapagliflozin Effect on CardiovascuLAR Events (DECLARE) trial, in which NT-proBNP was measured in 14,565 individuals with type 2 diabetes, of which 33% had elevated levels of NT-proBNP [35]. Here, NPPB is linked to type 2 diabetes mellitus.